Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 18, Issue 2, 2005, Pages 109-113

  Mega, Seiji ^a   Miyamoto, M ^a   Ebihara, Y ^a   Takahashi, R ^a   Hase, R ^a   Li, L ^a   Shichinohe, T ^a   Kawarada, Y ^a   Uehara, H ^a   Kaneko, H ^a   Hashimoto, H ^a   Murakami, Y ^a   Itoh, T ^b   Morikawa, T ^a   Kondo, S ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cyclin D1; E2F1; Esophageal squamous cell carcinoma; Immunohistochemistry; Prognosis

Indexed keywords

CYCLIN D1; TRANSCRIPTION FACTOR E2F1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CYCLIN D1; DISEASE PROGRESSION; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 22144482734     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2005.00463.x     Document Type: Article

References (27)

1. Collard J M, Otte J B, Fiasse R et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001; 234: 25-32.
2. Ando N, Iizuka T, Kakegawa T et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Sur 1997; 114: 205-9.
3. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232: 225-32.
4. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases. Prognostic significance of cyclin D1 and E-cadherin in patients with esophageal squamous cell carcinoma: multi-institutional retrospective analysis. J Am Coll Surg 2001; 192: 708-18.
5. Johnson D G, Schwarz J K, Cress W D, Nevins J R. Expression of transcription factor E2F-1 induces quiescent cells to enter S phase. Nature 1993; 365: 349-52.
6. Degregori J, Leone G, Ohtani K, Miron A, Nevins J R. E2F1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev 1995; 9: 2873-87.
7. Akervall J A, Michalides R J, Mineta H et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997; 79: 380-9.
8. Fracchiolla N S, Pruneri G, Pignataro L et al. Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: correlation of protein expression with lymph node metastases and advanced clinical stage. Cancer 1997; 79: 1114-21.
9. Zhang S Y, Caamano J, Cooper F, Guo X, Klein-Szanto A J. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 1994; 102: 695-8.
10. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer 1999; 81: 535-8.
11. Lai R, Medeiros L J, Coupland R, McCourty A, Brynes R K. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol 1998; 11: 457-63.
12. Kawahara K, Makimoto K, Maekawa T et al. An immunohistochemical examination of basaloid squamous cell carcinoma of the esophagus: report of a case. Surg Today 2001; 31: 655-9.
13. Hinds P W, Dowdy S F, Eaton E N, Arnold A, Weinberg R A. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994; 91: 709-13.
14. Cordon-Cardo C. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-60.
15. Weinberg R A. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-30.
16. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996; 8: 805-14.
17. Sherr C J. Cancer cell cycles. Science 1996; 274: 1672-7.
18. Shamma A, Doki Y, Shiozaki H et al. Effect of cyclin D1 and associated proteins on proliferation of esophageal squamous cell carcinoma. Int J Oncol 1998; 13: 455-60.
19. Slansky J E, Farnham P J. Introduction to the F2F family: protein structure and gene regulation. Curr Top Microbiol Immunol 1996; 208: 1-30.
20. Sobin L H, Wittekind C. UICC TNM classification of malignant tumors, 6th edn. New York: Wiley-Liss, 2002; 60-4.
21. Volante M, Croce S, Pecchioni C, Papotti M. E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors. Mod Pathol 2002; 15: 1038-43.
22. Saiz A D, Olvera M, Rezk S, Florentine B A, McCourty A, Brynes R K. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 2002; 198: 157-62.
23. Lai R, Mederiros L J, Wilson C S et al. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod Pathol 1998; 11: 642-7.
24. Ebihara Y, Miyamoto M, Shichinohe T et al. Overexpression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression. Dis Esophagus 2004; 17: 150-4.
25. Saito M, Helin K, Valentine M B, Griffith B B, Willman C L, Harlow E. Amplification of the E2F-1 transcription gene in the HEL erythroleukemia cell line. Genomics 1995; 25: 130-8.
26. Olshan A F, Weissler M C, Pei H et al. Alterations of the p16 gene in head and neck cancer: frequency and association with p53 PRAD-1 and HPV. Oncogene 1997; 14: 811-18.
27. Okami K, Reed A L, Cairns P et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 1999; 18: 3541-5.